Human iPSC-Derived cardiac organoids respond to urotensin II: Exploring a novel cardiac drug testing model

Area of Science:

• Cardiovascular Research
• Stem Cell Biology
• Organoid Technology

Background:

• Developing in vitro models that accurately replicate human heart complexity is crucial for disease modeling and drug development.
• Existing models often lack the multicellular composition and functional characteristics of native cardiac tissue.

Purpose of the Study:

• To create a self-assembled, multicellular human cardiac organoid model using induced pluripotent stem cells.
• To evaluate the model's utility for drug testing, cardiotoxicity screening, and studying heart disease pathophysiology.

Main Methods:

• Generation of human cardiac organoids from human induced pluripotent stem cells.
• In vitro characterization of the organoid's cellular composition (cardiomyocytes, endocardial/epicardial cells, fibroblasts, atrial/ventricular myocytes).
• Assessment of autonomous beating and simulation of cellular communication.

Main Results:

• The cardiac organoid model successfully recapitulated key features of the native human heart, including autonomous beating.
• The model demonstrated the ability to reveal drug-induced cardiotoxicity, exemplified by urotensin II, showing molecular changes similar to heart disease.
• Dynamic molecular changes observed in the organoids mirrored those in human heart disease patients.

Conclusions:

• The developed human cardiac organoid is a sophisticated model for studying heart disease progression.
• This model serves as a robust platform for drug testing and cardiotoxicity screening.
• The findings support the organoid's potential for advancing therapeutic strategies in cardiovascular medicine.